SIGA Technologies Inc
NASDAQ:SIGA

Watchlist Manager
SIGA Technologies Inc Logo
SIGA Technologies Inc
NASDAQ:SIGA
Watchlist
Price: 6.56 USD 2.66% Market Closed
Market Cap: 469.8m USD

SIGA Technologies Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SIGA Technologies Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
SIGA Technologies Inc
NASDAQ:SIGA
Interest Income Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$706m
CAGR 3-Years
N/A
CAGR 5-Years
20%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$1.5B
CAGR 3-Years
17%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
-$1.2B
CAGR 3-Years
19%
CAGR 5-Years
-20%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$461m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
10%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$705.2m
CAGR 3-Years
12%
CAGR 5-Years
-17%
CAGR 10-Years
-27%
No Stocks Found

SIGA Technologies Inc
Glance View

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
17.45 USD
Undervaluation 62%
Intrinsic Value
Price

See Also

Back to Top